Skip to Content

Tag Archives: FDA

Pfizer: A Shift in the Wind

More and more, it’s looking as if the worst is over for the pharmaceutical industry — and especially for the 800-pound gorilla, Pfizer (NYSE: PFE). Last Friday, a Food & Drug Administration advisory panel voted overwhelmingly (31-1) to recommend keeping PFE’s painkiller Celebrex on the market. The same panel also voted, by a slimmer (17-13) margin, to advise the FDA to allow continued sales of Pfizer’s other controversial cox-2 painkiller, Bextra.